Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer

Documenti analoghi

• Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis
  di: Stegeman, Inge, et al.
  Pubblicazione: (2015)
• A framework for organizing and selecting quantitative approaches for benefit-harm assessment
  di: Puhan, Milo A, et al.
  Pubblicazione: (2012)
• Benefits and harms of roflumilast in moderate to severe COPD
  di: Yu, Tsung, et al.
  Pubblicazione: (2013)
• Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
  di: Puhan, Milo A., et al.
  Pubblicazione: (2015)
• Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts
  di: Yebyo, Henock G., et al.
  Pubblicazione: (2018)